Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts

被引:10
|
作者
Rellick, Stephanie L. [2 ]
Piktel, Debbie [2 ]
Walton, Cheryl [2 ]
Hall, Brett [4 ]
Petros, William
Fortney, James E. [2 ]
Gencheva, Marieta
Denvir, Jim [5 ]
Hobbs, Gerald [5 ]
Craig, Michael
Gibson, Laura F. [1 ,2 ,3 ]
机构
[1] W Virginia Univ, Mary Babb Randolph Canc Ctr, Sch Med, Alexander B Osborn Hematopoiet Malignancy & Trans, Morgantown, WV 26506 USA
[2] W Virginia Univ, Canc Cell Biol Program, Morgantown, WV 26506 USA
[3] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA
[4] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[5] W Virginia Univ, Dept Stat, Morgantown, WV 26506 USA
关键词
Interleukin-6; Melphalan; Bone marrow microenvironment; Osteoblast; Bone marrow stromal cell; HEMATOPOIETIC STEM-CELL; MULTIPLE-MYELOMA; GROWTH-FACTOR; EXPRESSION; ENDOTHELIUM; SECRETION; ADHESION; NICHES; LINES; MICE;
D O I
10.1016/j.cyto.2012.01.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bone marrow stromal cells (BMSC) and osteoblasts are critical components of the microenvironment that support hematopoietic recovery following bone marrow transplantation. Aggressive chemotherapy not only affects tumor cells, but also influences additional structural and functional components of the microenvironment. Successful reconstitution of hematopoiesis following stem cell or bone marrow transplantation after aggressive chemotherapy is dependent upon components of the microenvironment maintaining their supportive function. This includes secretion of soluble factors and expression of cellular adhesion molecules that impact on development of hematopoietic cells. In the current study, we investigated the effects of chemotherapy treatment on BMSC and human osteoblast (HOB) expression of interleukin-6 (IL-6) as one regulatory factor. IL-6 is a pleiotropic cytokine which has diverse effects on hematopoietic cell development. In the current study we demonstrate that exposure of BMSC or HOB to melphalan leads to decreases in IL-6 protein expression. Decreased IL-6 protein is the most pronounced following melphalan exposure compared to several other chemotherapeutic agents tested. We also observed that melphalan decreased IL-6 mRNA in both BMSC and HOB. Finally, using a model of BMSC or HOB co-cultured with myeloma cells exposed to melphalan, we observed that IL-6 protein was also decreased, consistent with treatment of adherent cells alone. Collectively, these observations are of dual significance. First, suggesting that chemotherapy induced IL-6 deficits in the bone marrow occur which may result in defective hematopoietic support of early progenitor cells. In contrast, the decrease in IL-6 protein may be a beneficial mechanism by which melphalan acts as a valuable therapeutic agent for treatment of multiple myeloma, where IL-6 present in the bone marrow acts as a proliferative factor and contributes to disease progression. Taken together, these data emphasize the responsiveness of the microenvironment to diverse stress that is important to consider in therapeutic settings. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 50 条
  • [21] 17-BETA-ESTRADIOL INHIBITS INTERLEUKIN-6 PRODUCTION BY BONE MARROW-DERIVED STROMAL CELLS AND OSTEOBLASTS INVITRO - A POTENTIAL MECHANISM FOR THE ANTIOSTEOPOROTIC EFFECT OF ESTROGENS
    GIRASOLE, G
    JILKA, RL
    PASSERI, G
    BOSWELL, S
    BODER, G
    WILLIAMS, DC
    MANOLAGAS, SC
    JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (03): : 883 - 891
  • [22] Augmented production of interleukin-6 by normal human osteoblasts in response to CD34(+) hematopoietic bone marrow cells in vitro
    Taichman, RS
    Reilly, MJ
    Verma, RS
    Emerson, SG
    BLOOD, 1997, 89 (04) : 1165 - 1172
  • [23] Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study
    Brenda A Jensen
    Rebecca J Leeman
    Jennifer J Schlezinger
    David H Sherr
    Environmental Health, 2 (1)
  • [24] Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support
    Rodríguez, MDC
    Bernad, A
    Aracil, M
    BLOOD, 2004, 103 (09) : 3349 - 3354
  • [25] Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
    Jimi, E
    Nakamura, I
    Duong, LT
    Ikebe, T
    Takahashi, N
    Rodan, GA
    Suda, T
    EXPERIMENTAL CELL RESEARCH, 1999, 247 (01) : 84 - 93
  • [26] Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells
    Ara, Tasnim
    Song, Liping
    Shimada, Hiroyuki
    Keshelava, Nino
    Russell, Heidi V.
    Metelitsa, Leonid S.
    Groshen, Susan G.
    Seeger, Robert C.
    DeClerck, Yves A.
    CANCER RESEARCH, 2009, 69 (01) : 329 - 337
  • [27] Inverse correlation of interleukin-6 with soluble interleukin-6 receptor after transplantation of bone marrow or peripheral blood stem cells
    Steffen, M
    Pichlmeier, U
    Zander, A
    BONE MARROW TRANSPLANTATION, 1997, 20 (09) : 715 - 720
  • [28] Inverse correlation of interleukin-6 with soluble interleukin-6 receptor after transplantation of bone marrow or peripheral blood stem cells
    M Steffen
    U Pichlmeier
    A Zander
    Bone Marrow Transplantation, 1997, 20 : 715 - 720
  • [29] Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells
    Xie, Zhongyu
    Tang, Su'an
    Ye, Guiwen
    Wang, Peng
    Li, Jinteng
    Liu, Wenjie
    Li, Ming
    Wang, Shan
    Wu, Xiaohua
    Cen, Shuizhong
    Zheng, Guan
    Ma, Mengjun
    Wu, Yanfeng
    Shen, Huiyong
    STEM CELL RESEARCH & THERAPY, 2018, 9
  • [30] Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells
    Zhongyu Xie
    Su’an Tang
    Guiwen Ye
    Peng Wang
    Jinteng Li
    Wenjie Liu
    Ming Li
    Shan Wang
    Xiaohua Wu
    Shuizhong Cen
    Guan Zheng
    Mengjun Ma
    Yanfeng Wu
    Huiyong Shen
    Stem Cell Research & Therapy, 9